Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquin Mateo; Nuria Porta; Diletta Bianchini; Ursula McGovern; Tony Elliott; Robert Jones; Isabel Syndikus; Christy Ralph; Suneil Jain; Mohini Varughese; Omi Parikh; Simon Crabb; Angus Robinson; Duncan McLaren; Alison Birtle; Jacob Tanguay; Susana Miranda; Ines Figueiredo; George Seed; Claudia Bertan; Penny Flohr; Berni Ebbs; Pasquale Rescigno; Gemma Fowler; Ana Ferreira; Ruth Riisnaes; Rita Pereira; Andra Curcean; Robert Chandler; Matthew Clarke; Bora Gurel; Mateus Crespo; Daniel Nava Rodrigues; Shahneen Sandhu; Aude Espinasse; Peter Chatfield; Nina Tunariu; Wei Yuan; Emma Hall; Suzanne Carreira; Johann S de Bono

Journal article

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese, Omi Parikh, Simon Crabb, Angus Robinson, Duncan McLaren, Alison Birtle, Jacob Tanguay, Susana Miranda, Ines Figueiredo, George Seed, Claudia Bertan Show all

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2020

DOI: 10.1016/S1470-2045(19)30684-9

University of Melbourne Researchers

Shahneen Sandhu Author The Sir Peter MacCallum Department of Oncology

Grants

Funding Acknowledgements

Cancer Research UK, AstraZeneca, Prostate Cancer UK, the Prostate Cancer Foundation, the Experimental Cancer Medicine Centres Network, and the National Institute for Health Research Biomedical Research Centres.